This is a regulatory intimation regarding an Investor Presentation for an Earnings Call that was previously scheduled.

The Earnings Call with Analysts/Investors was scheduled for Wednesday, September 02, 2026 at 4:00 p.m. (IST) to discuss the Unaudited (Standalone and Consolidated) Financial Results for the quarter ended June 30, 2026 (Q1 FY27).

The document encloses the Investor Presentation for this call, filed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The presentation includes Q1 FY27 Financial Performance highlights:

  • Consolidated operating revenue grew by 31.34% YoY to ₹70.36 Cr
  • EBITDA increased by 62.16% YoY to ₹19.80 Cr, with margin at 28.14%
  • Net profit rose by 59.31% YoY to ₹16.25 Cr; EPS stood at ₹5.07
  • Performance driven by improved capacity utilization, operational efficiencies, and higher realizations

FY26 Performance highlights were also provided for context:

  • Consolidated operating revenue increased by 22.9% YoY to ₹215.45 Cr
  • PAT grew by 18.3% YoY to ₹50.27 Cr; EPS increased to ₹15.67
  • EBITDA margin of 20.5% and PAT margin of 21.8% during FY26

Management Commentary from Mr. Suresh Kalra (Managing Director & CEO) attributed the strong performance to higher capacity utilization, better realizations, strategic expansion initiatives, and steady domestic demand.

Post-Quarter Developments announced:

  • The Board approved the Scheme of Amalgamation of its wholly owned subsidiary, Indoborax Infrastructure Private Limited, with Indo Borax & Chemicals Ltd.
  • The Board approved the acquisition of 64.26% equity shares of Kronox Lab Sciences (a Vadodara-headquartered listed specialty chemicals player)
  • Acquisition involves 2,38,44,000 equity shares for an aggregate consideration of ₹246.12 Cr
  • The Board also approved making an Open Offer along with Zenrock Chemicals Limited (as a PAC) for acquisition of up to 95,70,000 equity shares of Kronox Lab Sciences, representing a 25.79% stake

Mr. Suresh Kalra described the Kronox acquisition as a strategic move to utilize Kronox's experience and export presence. Kronox brings 185+ speciality chemical products, export presence and FY26 revenue/PAT of ₹101 Cr/~₹28 Cr.

The presentation also included information about the company's diversified boron-based product portfolio, management team bios, and market positioning.

Additional Notes Section

The document includes the enclosed Investor Presentation deck.

Financial data for Q1 FY27 and FY26 was disclosed in the presentation.

The document is signed by Pravin Prabhakar Chavan, Company Secretary & Compliance Officer (M. No. A16857).